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ABSTRACT The caveolins are a family of related proteins that form the structural
framework of caveolae. They have been implicated in the regulation of signal transduc-
tion, cell cycle control, and cellular transport processes, particularly cholesterol traffick-
ing. Caveolin-1 is expressed by a variety of cell types, including Schwann cells, although
its expression is greatest in differentiated cell types, such as endothelial cells and
adipocytes. In the present work, we characterize caveolin-1 expression both during rat
sciatic nerve development and after axotomy. Schwann cells express little caveolin-1 on
postnatal days 1 and 6. By P30, myelinating Schwann cells express caveolin-1, which is
localized in the outer/abaxonal myelin membranes as well as intracellularly. After
axotomy, Schwann cell caveolin-1 expression in the distal nerve stump decreases as
Schwann cells revert to a premyelinating (p75-positive) phenotype; residual caveolin-1
within the nerve largely localizes to myelin debris and infiltrating macrophages.
We speculate that caveolin-1 plays a role in the biology of myelinating Schwann cells.
GLIA 38:191–199, 2002. © 2002 Wiley-Liss, Inc.
INTRODUCTION
During development, Schwann cells (SC) are regu-
lated by axon-derived signals. In embryonic nerve, SC
precursors are first apparent at E14–15, giving rise to
S-100-positive immature/premyelinating SC at E15–
17; postnatally, these SC will give rise to myelinating
and nonmyelinating SC (Jessen and Mirsky, 1991).
Premyelinating SC can proliferate and are distin-
guished by markers such as the low-affinity nerve
growth factor receptor, or p75 (Jessen and Mirsky,
1999a). As SC establish contact with large-diameter
axons, they withdraw from the cell cycle and myelin
synthesis ensues, with the first myelin wraps forming
during the initial 24 h (Jessen and Mirsky, 1991); this
stage is characterized by the expression of myelin pro-
teins such as P0 and myelin-associated glycoprotein
(MAG) (Jessen et al., 1991; Webster, 1993) and the loss
of p75 expression (Taniuchi et al., 1986). After nerve
transection, previously myelinating SC cease to ex-
press P0 and MAG and appear to revert to a dediffer-
entiated, premyelinating phenotype (Mirsky and Jes-
sen, 1990; S. Scherer and Asbury, 1993; S. Scherer and
Salzer, 1996; Jessen and Mirsky, 1999b).
Caveolae are plasma membrane microdomains en-
riched in cholesterol, glycosphingolipids, signaling mol-
ecules, and the caveolins. Caveolins not only provide
the structural framework of caveolae (Lisanti et al.,
1993); they also regulate multiple signal transduction
processes (Okamoto et al., 1998). Of the known caveo-
lins, caveolin-1 has been most studied (Glenney and
Soppet, 1992; P. Scherer et al., 1996; Tang et al., 1996).
There are two caveolin-1 isoforms, 24 kDa () and 21
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kDa (), generated from two separate transcripts (Kogo
and Fujimoto, 2000). Caveolin-1 binds to itself to form
a multimeric complex (Fra et al., 1995), serving as a
scaffold for a variety of signaling molecules including
growth factor receptors and downstream signaling mol-
ecules (Sargiacomo et al., 1995). In many cell types,
caveolin-1 levels correlate with the degree of differen-
tiation (Fan et al., 1983; P. Scherer et al., 1995; Song et
al., 1996). Cells transformed by a variety of stimuli
exhibit significantly decreased caveolin-1 levels, while
caveolin-1 transfection into transformed cells results in
a less malignant phenotype, suggesting a growth-reg-
ulating function (Koleske et al., 1995; Lee et al., 1998;
Okamoto et al., 1998).
Caveolin-1 plays a central role in the regulation of
cholesterol transport, mediating its efflux in fibroblasts
(Murata et al., 1995; Uittenbogaard et al., 1998). The
myelin sheath is particularly enriched in cholesterol,
which appears to be synthesized by the SC themselves
(Fu et al., 1998). Because myelinating SC have a much
greater need for cholesterol biosynthesis than do dedi-
fferentiated SC (Goodrum, 1990), which do not synthe-
size myelin, it is reasonable to speculate that myelinat-
ing SC require increased caveolin-1 expression for
cholesterol homeostasis.
SC are an appealing cell type in which to study the
relationship between caveolin-1 expression and cell
phenotype, as SC will dedifferentiate and reenter the
cell cycle after axotomy (S. Scherer and Salzer, 1996).
Their dedifferentiation is accompanied by a decrease in
the expression of myelin-related proteins and their cog-
nate mRNAs. We have previously shown that myeli-
nating SC in adult rat sciatic nerve (SN) express caveo-
lin-1 (Mikol et al., 1999). In the present study, we
explore caveolin-1 expression within the context of rat
SC differentiation and dedifferentiation and find that




An affinity-purified rabbit antiserum against caveo-
lin-1 (C13630), which recognizes both the - and the
-isoforms of caveolin-1, was obtained from Transduc-
tion Laboratories (Lexington, KY). The anti-S-100
monoclonal antibody (mAb) was purchased from Sigma
(St. Louis, MO; S-2532); an anti-p75 mAb was obtained
from Calbiochem (La Jolla, CA; GR10); and the ED1
mAb, which recognizes a lysosomal membrane protein
of myeloid cells, particularly macrophages, was ob-
tained from Serotec (Raleigh, NC). The anti-P0 mAb
and the anti-MAG antiserum were kindly provided by
Drs. Juan Archelos (Max Planck Institute for Psychia-
try, Munich, Germany) and James Salzer (New York
University, New York), respectively.
RT-PCR
SC were isolated from postnatal day 3 (P3) Sprague-
Dawley rats (Harlan-Sprague-Dawley, Indianapolis,
IN), cultured on poly-L-lysine-coated plates, and main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
with 10% fetal bovine serum (FBS), supplemented with
6 mM L-glutamine, 2 M forskolin, and 10 g/ml pitu-
itary extract (Sigma) (Brockes et al., 1979; Porter et al.,
1986). Cells were grown at 37°C in a humidified atmo-
sphere with 10% CO2 and grown to 80% confluency
before cell lysates were collected. Total RNA was ex-
tracted from SC, using the guanidine isothiocyanate
method (Chomczynski and Sacchi, 1987), and 2 g was
used to synthesize cDNA with Superscript II (Gibco-
BRL Products, Gaithersburg, MD). Oligonucleotides
used for reverse transcriptase-polymerase chain reac-
tion (RT-PCR) were designed such that they fell within
the 5 and 3 noncoding regions of the rat caveolin-1
cDNA (Accession no. Z46614) and were common to both
the - and -isoforms. The oligonucleotide used for
generation of template was CCTCCATCCCTGAAAT-
GTCACTAT, and the primers used for subsequent PCR
were CATAGGATCCAGAGCCTGCAGCCAGCCACG
(5) and CATAGAATTCATCCCTGAAATGTCACTA-
TATCT (3), with internal BamHI and EcoRI restric-
tion sites underlined, respectively, to facilitate cloning.
For PCR amplification of cDNA template, high-fidelity
Pfu polymerase (Stratagene, La Jolla, CA) was used.
Product was restriction-digested with BamHI and
EcoRI (Boehringer-Mannheim, Indianapolis, IN), gel-
extracted, and then ligated into Bluescript vector
(Stratagene) that had first been digested with BamHI
and EcoRI. Clones were fully sequenced in both direc-
tions, using custom complementary primers and an
automated DNA sequencer in the DNA Sequencing
Core Facility at the University of Michigan.
Immunoblotting
SN was obtained from P1, P10, P35, and P90
Sprague-Dawley rats. In some cases, the perineurium
was removed before homogenization. Nerves were dis-
rupted with a Dounce homogenizer (6–8 strokes each,
loose pestle followed by tight pestle) and then sonicated
for three 10-s bursts. Protein was extracted using pro-
tease and phosphatase inhibitors (Mikol et al., 1999)
and quantitated using a Protein Assay kit (Bio-Rad,
Richmond, CA). SN lysates were analyzed by immuno-
blotting after sodium dodecyl sulfate-polyacrylamide
electrophoresis (SDS-PAGE) and electrical transfer of
proteins onto nitrocellulose (Mikol et al., 1999). Nitro-
cellulose sheets were probed with an affinity-puri-
fied rabbit antiserum against caveolin-1 (1:2,500), fol-
lowed by peroxidase-conjugated secondary antibodies
(1:2,500; Santa Cruz Biotechnology) and visualization
by enhanced chemiluminescence (ECL). We similarly
prepared immunoblots of normal SN and the distal
stumps of lesioned adult rat SN (12 days post-transec-
192 MIKOL ET AL.
tion). Identical blots were prepared and hybridized
with rabbit antisera against caveolin-1 (1:2,500) or
MAG (1:2,500). Positive and negative control lysates
were immunoblotted along with SN lysates, and paral-
lel immunoblots were incubated in the absence of pri-
mary antibody (conjugate controls).
Immunohistochemistry
SN were removed from P1, P6, P30, and P90
Sprague-Dawley rats and frozen in OCT compound
(Ted Pella, Redding, CA). The distal stumps of adult
nerves were similarly collected 12 days post-axotomy
(transection). Sections were first fixed in 4% parafor-
maldehyde and then immunostained as previously
described (Mikol et al., 1999). Antibodies against
caveolin-1, S-100, ED1, and P0 were all used at 1:500.
Cy-3- and fluorescein isothionate (FITC)-conjugated
secondary antisera (Jackson Immunoresearch, West-
grove, PA) were used at 1:100. Conjugate controls were
done in parallel. Slides were coverslipped and viewed
by fluorescence microscopy using a Leitz fluorovert mi-
croscope (W. Nuhsbaum, McHenry, IL).
RESULTS
Expression of Caveolin-1 in Developing
Sciatic Nerve
We demonstrated previously that caveolin-1 is
present in rat SC, using affinity-purified antibodies
(Mikol et al., 1999). To show that SC express caveolin-1
mRNA, we performed RT-PCR on RNA from cultured
rat SC with the high-fidelity polymerase Pfu (Fig. 1).
Upon sequencing two clones from two different RT-
PCR reactions, we obtained the identical sequence,
which matches that for rat caveolin-1  in the Gen-
Bank database (Accession no. Z46614), except for a
single nucleotide difference (G3873C) that would be
predicted to cause a Gly120 3 Ala substitution. This
difference may represent a polymorphism, as we have
cloned caveolin-1 from Sprague-Dawley rats, while the
reported GenBank sequence was derived from a Nor-
way rat. We detected only caveolin-1  in cultured SC.
Because caveolin-1 expression increases during dif-
ferentiation of many cell types (Fan et al., 1983; P.
Scherer et al., 1995; Song et al., 1996), we wished to
determine whether caveolin-1 expression by SC in-
creases during myelination. Whereas the 8% acryl-
amide gels we previously used did not separate the two
caveolin-1 isoforms, these were resolved on 12% gels.
Immunoblot analysis of whole SN from P1, P10, P35,
and P90 rats is shown in Figure 2.
Qualitatively, caveolin-1 content increases modestly
at best during development; however, any change in
SC-derived caveolin-1 could be obscured by the pres-
ence of substantial caveolin-1 from perineurium and
blood vessels at all ages (Reale et al., 1975; Lisanti et
al., 1994; Mikol et al., 1999).
Given these possible limitations of immunoblot anal-
ysis, we examined caveolin-1 expression by immuno-
fluorescence. For this purpose, sections of rat SN ob-
tained at ages similar to those used for immunoblotting
were double-labeled for caveolin-1 and P0. This analy-
sis was performed three times; the temporal progres-
sion of caveolin-1 expression and its spatial relation-
ship to P0 are best illustrated in transverse sections
(Fig. 3). At P1, caveolin-1 is expressed minimally
within the endoneurium, but there is prominent stain-
ing of blood vessels and perineurium, which persists at
all ages examined. P0 staining is relatively weak at P1,
reflecting sparse myelination; P0 and caveolin-1 do not
overlap. At P6, caveolin-1 expression by SC becomes
apparent. In some instances, it closely opposes or sur-
rounds the P0-positive myelin sheaths. Caveolin-1
staining of myelinating SC is widespread at P30, when
myelination is essentially complete (Hahn et al., 1987).
Between P30 and P90, we did not appreciate a change
in either the amount of caveolin-1 expression or its
localization in myelinating SC: caveolin-1 is present
Fig. 1. Caveolin-1 mRNA expression. Reverse transcription-poly-
merase chain reaction (RT-PCR) (semiquantitative) of RNA from lung
and Schwann cells (SC) yields a single product of 0.6 kb in each case.
Caveolin-1 mRNA is more abundant in lung than in SC. A 123-bp
DNA ladder is shown on the right.
Fig. 2. Immunoblot analysis of caveolin-1 expression in developing
sciatic nerve (SN). Lysates of whole rat SN obtained at P1, P10, P35,
and P90 (40 g each)were immunoblotted with an anti-caveolin-1
antiserum. Both caveolin-1  (24 kDa)and  (21 kDa) isoforms in-
crease modestly during development.
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largely in abaxonal membranes and in regions within
the SC that surround P0-positive myelin sheaths.
Expression of Caveolin-1 in Degenerating Nerve
To investigate caveolin-1 expression in axotomized
nerve, distal nerve stumps were collected 12 days after
axotomy, because previous work has shown that at this
time SC have largely reverted to a premyelinating phe-
notype (S. Scherer et al., 1995). We performed immu-
noblot analysis using perineurium-free SN, hypothe-
sizing that any change in SC caveolin-1 expression
would be more apparent if the non-SC content of SN
were minimized. Although one cannot remove the en-
doneurial blood vessels, much of the perineurium can
be removed from adult SN. As shown in Figure 4, there
is a clear decrease in the caveolin-1 content of peri-
neurium-free SN after axotomy, especially regarding
the -isoform; this finding was confirmed by perform-
ing the experiment three times. For comparison, we
examined the level of MAG in normal and transected
nerve by immunoblot analysis; as expected, MAG lev-
els decrease after axotomy (Fig. 4).
Immunohistochemical analysis of transected nerve
provides more dramatic results. As shown in Figure 5,
Fig. 3. Localization of caveolin-1 in developing sciatic nerve (SN).
Transverse sections of P1 (A–C), P6 (D–F), P30 (G–I), and P90
(J–L) rat SN were double immunostained with a rabbit antiserum
against caveolin-1 (B,E,H,K), an anti-P0 monoclonal antibody
(mAb) (A,D,G,J), or both (C,F,I,L). At P1 and P6, caveolin-1 is
mainly localized to the endoneurial blood vessels (V) and peri-
neurium (P); the P0-positive myelin sheaths (arrows) are not
stained. At P30 and P90, caveolin-1 localizes to the Schwann
cell (SC) bodies and abaxonal membranes (arrowheads). Scale
bar  20 M.
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12 days after axotomy, P0 is localized to the degener-
ating myelin sheaths, which are found in macrophages
(Griffin et al., 1993). Caveolin-1 is also extremely re-
duced; the linear appearance of caveolin-1 immunore-
activity seen in longitudinal sections of normal nerve
(Mikol et al., 1999) is absent. Some caveolin-1 staining
colocalizes with P0-positive myelin debris, suggesting
that it is localized in macrophages, which we directly
confirmed by double-labeling sections for caveolin-1
and ED1, a marker of macrophages (Fig. 6). This caveo-
lin-1 could have originated within the macrophages
themselves (Matveev et al., 1999), or it could reflect
residual caveolin-1 from phagocytosed myelinating
SCs, as previously noted for periaxin, a membrane-
associated protein expressed by myelinating SCs (S.
Scherer et al., 1995). It should be noted that there was
no apparent change in caveolin-1 immunoreactivity of
blood vessels and perineurium during development or
after axotomy.
In further characterizing changes in caveolin-1 ex-
pression after axotomy, we compared caveolin-1 local-
ization with that of p75. In adult rat SN, only nonmy-
elinating SC express p75 (Jessen and Mirsky, 1992;
Jessen et al., 1994). However, in distal stumps ob-
tained 12 days after transection, p75-positive “dener-
vated” SC are numerous, allowing direct comparison
between the expression patterns of caveolin-1 and p75
(Fig. 5G,H). In all instances, p75-positive membranes
are negative for caveolin-1-immunoreactivity. Thus, in
contrast to myelinating SC, “denervated” SC do not
express significant caveolin-1.
DISCUSSION
We have confirmed and extended our previous find-
ings that SCs express caveolin-1 (Mikol et al., 1999).
We have cloned and sequenced caveolin-1 cDNA from
cultured rat SC. Although immunoblot analysis dem-
onstrates only a modest increase in caveolin-1 during
postnatal development (owing to abundant caveolin-1
expression by blood vessels and perineurium), immu-
nostaining demonstrates a progressive increase in
caveolin-1 expression during myelination, slightly lag-
ging P0 expression. Caveolin-1 is localized to the outer/
abaxonal SC membrane and within SCs (surrounding
compact myelin). After axotomy, residual caveolin-1
expression in axotomized nerve is mainly associated
with myelin debris and macrophages.
Myelinating SC Express Caveolin-1
The above data document that caveolin-1 protein
expression is fundamentally linked to the myelinating
phenotype of SC. Caveolin-1 is found in myelinating
SC, but not in premyelinating SC in early postnatal
development or in denervated SC after nerve transec-
tion. This pattern of expression has been observed for
many other myelin-related proteins, including P0,
PMP22, MBP, MAG, connexin32, periaxin, 4 integrin,
and Egr-2/Krox20 (Feltri et al., 1994; S. Scherer and
Asbury, 1993; S. Scherer et al., 1995; S. Scherer and
Salzer, 1996; S. Scherer, 1997; Mirsky and Jessen,
1990, 1999; Jessen et al., 1999; Notterpek et al., 1999),
and has been taken as evidence that (1) the protein
plays an important role in myelinating SC; and (2)
axon–SC interactions are required to maintain expres-
sion (S. Scherer et al., 1996).
Caveolin-1 and Proliferation
The expression of caveolin-1 expression in myelinat-
ing SC is consistent with the theme that its expression
correlates with the level of cellular differentiation (Fan
et al., 1983; P. Scherer et al., 1994, 1995; Mikol et al.,
1999). For example, caveolin-1 is induced 25-fold when
NIH 3T3-L1 fibroblasts differentiate into adipocytes,
and in a variety of transformed cells its levels correlate
inversely with the degree of oncogenic transformation
and anchorage-independent growth (Koleske et al.,
1995; Engelman et al., 1997; Lee et al., 1998). After a
period of active proliferation of SC precursors during
development, SC that associate with large axons cease
dividing and form a myelin sheath (Jessen and Mirsky,
1991). After axotomy, SC revert to a precursor pheno-
type; i.e., they become P0-negative and p75-positive
and reenter the cell cycle (Jessen and Mirsky, 1991,
Jessen and Mirsky, 1992). Within this context, it may
be relevant that caveolin-1 can suppress proliferation
(Fielding et al., 1999; Bist et al., 2000). Caveolin-1 also
modulates a variety of signal transduction pathways,
largely functioning as a negative regulator of signal
transduction. Caveolin-1 reduces signaling through the
erbB2/neu receptor (Engelman et al., 1998b) and its
downstream effectors, phosphatidylinositol 3-kinase
Fig. 4. Immunoblot analysis of perineurium-free sciatic nerve (SN).
Lysates were prepared from an adult rat (P90) SN and an adult rat 12
days post-transection (12d PT); the nerves were stripped of peri-
neurium to enrich for proteins expressed by Schwann cells. Two
identical blots (using 40 g lysate per lane) were prepared and probed
with rabbit antisera against caveolin-1 (Cav-1) and myelin-associated
glycoprotein (MAG). Whereas the level of MAG (100 kDa) is mark-
edly decreased after axotomy, the level of caveolin-1 is less dimin-
ished, especially the -isoform. The experiment was performed three
times with similar results.
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(Zundel et al., 2000) and mitogen-activated protein ki-
nase (Engelman et al., 1997, 1998a) activity, all of
which have been implicated in proliferation and sur-
vival of SC (Baek and Kim, 1998; Delaney et al., 1999;
Cheng et al., 2000; Garratt et al., 2000; Maurel and
Salzer, 2000). Thus, the loss of caveolin-1 expression by
Fig. 5. Denervated Schwann
cells (SCs) do not express caveo-
lin-1. These are photomicrographs
of transverse (A,C,E,G) and longi-
tudinal (B,D,F,H) sections of rat
sciatic nerve (SN) 12 days after
axotomy, immunostained for ei-
ther caveolin-1 (A,B), P0 (C,D),
caveolin-1 and P0 (E,F), or caveo-
lin-1 and p75 (G,H). Compared
with intact adult nerve (Fig. 3),
caveolin-1 expression within the
endoneurium is markedly de-
creased (arrowheads), and in some
cases colocalizes with P0-positive
myelin debris (arrows, A–F). In
contrast, caveolin-1 immunoreac-
tivity within perineurium (P) and
endoneurial blood vessels (V) re-
mains intense. As G and H illus-
trate, caveolin-1 (arrowheads) and
p75 (arrows) are not co-localized,
indicating that denervated SC do
not express caveolin-1. Scale bar 
20 M.
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SC after axotomy may enable dedifferentiated SC to
proliferate.
Caveolin-1 and Cholesterol
Another possible role of caveolin-1 in myelinating SC
relates to the regulation of cholesterol transport. Cho-
lesterol synthesis by SC increases during myelination
and decreases when SC dedifferentiate (Goodrum,
1990). Caveolae are highly enriched in cholesterol
(Simionescu et al., 1983), and the structure and func-
tion of caveolae are dependent on membrane choles-
terol (Li et al., 1996; Hailstones et al., 1998; Rothberg
et al., 1990, 1992). Caveolin-1 itself is a cholesterol-
binding protein (Murata et al., 1995), mediating cho-
lesterol transport from the Golgi network to the plasma
membrane in fibroblasts (Fielding et al., 1995, Fielding
and Fielding, 1997) and cooperating with the high-
density lipoprotein-binding protein SR-B1 (which is
enriched in caveolae) in maintaining cholesterol ho-
meostasis (Matveev et al., 1999). While it is not yet
clear what factors regulate caveolin-1 levels in SC, in
non-neural cells cellular cholesterol concentration is
critical. In fibroblasts, caveolin-1 expression varies in-
versely with the cellular free sterol level in order to
facilitate cholesterol efflux as concentrations rise
(Fielding et al., 1995, 1997; Fielding and Fielding,
1997); further, reciprocal changes in caveolin-1 and
cholesterol have been identified during cell cycle pro-
gression (Fielding et al., 1999; Bist et al., 2000). Recent
work has identified sterol regulatory element-like se-
quences and overlapping E2F- and Sp1-like sequences
in the promoter region of caveolin-1 (Bist et al., 1997;
Fu et al., 1998), the latter of which are known to have
important effects in control of cell cycle regulation;
deletion of this region abolishes cell cycle dependent
changes in caveolin-1 expression (Fielding et al., 1999;
Bist et al., 2000).
These findings are interesting in light of previous
work that has shown that tellurium, an inhibitor of
cholesterol biosynthesis at the squalene epoxidase
step, causes reversible peripheral nerve demyelination
in young rats, accompanied by downregulation of my-
Fig. 6. Residual caveolin-1 is local-
ized to macrophages. Photomicrographs
of transverse (A,B) and longitudinal
(C,D) sections of rat sciatic nerve (SN)
12 days after axotomy, immunostained
with an ED1 mAb that recognizes mac-
rophages (A,C) or rabbit antiserum
against caveolin-1 (B,D). Residual
caveolin-1 (arrowheads) partially colo-
calizes with ED1 (arrows), indicative of
macrophages that have infiltrated the
nerve. Scale bar  20 M.
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elin proteins, upregulation of p75, and SC prolifera-
tion, as SC revert to a precursor phenotype (Wagner-
Recio et al., 1991; Toews et al., 1992). The rather
selective toxicity to peripheral nerve has been attrib-
uted to the relative demands for cholesterol synthesis,
with myelin synthesis proceeding rapidly in the periph-
eral nerves of weanling rats. It has been assumed that
the demyelinating effect of cholesterol lowering in my-
elinating SC is direct, i.e., caused by structural factors,
although an intriguing possibility is that cholesterol
lowering results in decreased caveolin-1 expression, SC
dedifferentiation and proliferation, and subsequent de-
myelination. Given that caveolin-1 and cholesterol may
together regulate cell cycle regulation, caveolin-1 up-
regulation in myelinating SC is consistent with its
potential role in differentiation and cholesterol trans-
port, while its downregulation in the setting of demy-
elination may enable dedifferentiation and cell prolif-
eration. To our knowledge, caveolin-1 expression has
not been studied in the tellurium model of demyelina-
tion.
Compelling evidence for a link between cellular
cholesterol homeostasis and caveolin expression in
vivo comes from research on Niemann-Pick type C
(NPC) disease, which in humans causes a progres-
sive demyelinating disorder. Mutations in the mu-
rine NPC gene lead to altered expression of NPC1, a
membrane protein that has a cholesterol-sensing do-
main (Garver et al., 1997). Homozygotes lacking
NPC1 exhibit greatly increased free cholesterol lev-
els and a slight increase in caveolin-1 expression,
while heterozygotes show near-normal cholesterol
levels but greatly increased caveolin-1, the latter
presumably reflecting a compensatory response to
maintain cholesterol balance that homozygotes are
not able to withstand in light of significantly ele-
vated free cholesterol and absent NPC1.
Taken together with our data, these findings suggest
an intimate connection between caveolin-1 expression
and SC phenotype. We hypothesize that caveolin-1
plays an important role in myelinating SC, such as
regulation of signal transduction, cell cycle control, and
growth regulation and/or cholesterol transport. Future
work will investigate the molecular mechanisms
whereby caveolin-1 modulates SC phenotype.
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